The role of AMH in the pathophysiology of polycystic ovarian syndrome. Issue 1 (July 2016)

• Record Type: Journal Article
• Authors: Garg, Deepika; Tal, Reshef
• Is Part Of: Reproductive biomedicine online. Volume 33:Issue 1(2016)
• Page Start: 15
• Page End: 28
• Publication Date: 2016-07
• Subjects: AMH -- hyperandrogenism -- insulin resistance -- ovulatory dysfunction -- pathophysiology -- PCOS; Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2016.04.007
• Languages: English
• ISSNs: 1472-6483

Abstract

Abstract: Polycystic ovarian syndrome (PCOS) affects 5 − 10% of reproductive age women, but its pathogenesis is still poorly understood. The aim of this review is to collate evidence and summarize our current knowledge of the role of anti-Müllerian hormone (AMH) in PCOS pathogenesis. AMH is increased and correlated with the various reproductive and metabolic/endocrine alterations in PCOS. AMH plays an inhibitory role in follicular development and recruitment, contributing to follicular arrest. AMH inhibitory action on FSH-induced aromatase production likely contributes to hyperandrogenism in PCOS, which further enhances insulin resistance in these women. Elevated serum AMH concentrations are predictive of poor response to various treatments of PCOS including weight loss, ovulation induction and laparoscopic ovarian drilling, while improvement in various clinical parameters following treatment is associated with serum AMH decline, further supporting an important role for AMH in the pathophysiology of this syndrome. This review emphasizes the need for understanding the exact mechanism of action of AMH in the pathophysiology of PCOS. This may lead to the development of new treatment modalities targeting AMH to treat PCOS, as well as help clinicians in prognostication and better tailoring existing treatments for this disease.